Neola Medical EN
  • Lung Monitoring
  • The technology
  • Our Studies
  • About Us
  • Career
  • Investors
    • To invest in Neola Medical
    • Risks and uncertainties
    • Stock information
    • Annual General Meeting (Swedish)
    • Corporate governance
    • Certified Adviser
    • Rights Issues (Swedish)
      • Riktad Emission 2023
      • Företrädesemission 2022
      • IPO 2020
        • Teckningsoptioner av serie TO1
    • Investor Relations
    • Investor letters
    • Presentations
    • Press Releases
    • Reports and Financial Calendar
  • News
    • Press Releases
    • Articles and posts
      • 2018 – 2024
Select Page

Investor letters

Here you can read our investor letters that are released about four times a year.

2024

  • Spring 2024
  • Summer 2024
  • Autumn 2024

2023

  • Spring 2023
  • Summer 2023
  • Autumn 2023
  • Winter 2023

2022

  • Spring 2022
  • Autumn 2022
  • Winter 2022

2021

  • Spring 2021
  • Summer 2021
  • Autumn 2021
  • Winter 2021
About Neola Medical

Neola Medical AB (publ) is revolutionizing neonatal intensive care with Neola®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume changes and oxygen gas concentration. Neola® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

Sweden, HQ

Neola Medical AB
Ideon Gateway
Scheelevägen 27
223 63 Lund
info@neolamedical.com

U.S. Office

Neola Medical, Inc.
Nordic Innovation House
470 Ramona Street PMB
Palo Alto CA 94301-1707
info@neolamedical.com

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPersonal Data Policy